

## SynAct Pharma to host Capital Markets Day in Stockholm on March 11

**SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it will host a Capital Markets Day on March 11, 15:00-17:00 CET in Stockholm.**

*"With key clinical data expected from the ADVANCE study and ongoing studies in respiratory viral infections and dengue virus, we are looking at a particularly busy and transformative year for SynAct," said Jeppe Øvlesen, Chief Executive Officer, SynAct Pharma*

The capital markets day will provide investors, analysts, and the media with an update on SynAct's clinical development programs and priorities focused on resomelagon applications in rheumatoid arthritis and respiratory viral infections.

When: March 11, 2026, from 15:00-17:00 CET

Location: Investor Studios, Hötorgsskrapan 3

Address: Sveavägen 9 or Mäster Samuelsgatan 42 or Sergelgatan 8 – 10, Floor 7

Further details regarding the agenda, speakers, livestream link, and registration will be communicated closer to the event.

**For further information, please contact:**

Jeppe Øvlesen

CEO, SynAct Pharma AB

Phone: + 45 2844 7567

E-mail: [investor.relations@synactpharma.com](mailto:investor.relations@synactpharma.com)

**About SynAct Pharma AB**

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: <https://synactpharma.com/>.

**Attachments**

[SynAct Pharma to host Capital Markets Day in Stockholm on March 11](#)